Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03341078 · ClinicalTrials.gov registry record · Phase 2

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

A Phase 2 study, sponsored by VA Office of Research and Development.

Completed
Registry status
Phase 2
Development phase
176
Enrollment target

NCT03341078: Completed Phase 2 study, sponsored by VA Office of Research and Development.

NCT03341078 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 176 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03341078, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
Phase 2
Development phase
176 participants
Enrollment target

Study Summary

Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.

Primary Outcome

Pre and post differences in brain function will be assessed.

Interventions

  • DRUG Placebo Oral Tablet
  • DRUG Ibudilast

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2019-05-01
Est. Completion 2025-10-15
Phase Phase 2
VA Office of Research and Development

1,668 total trials

What the finished NCT03341078 record still lists

NCT03341078 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.

NCT03341078 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03341078 about?

NCT03341078 is a clinical study titled "Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users". Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that...

What is the current status of trial NCT03341078?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2019-05-01. Estimated completion is 2025-10-15.

What interventions are being tested in trial NCT03341078?

The interventions under investigation include: Placebo Oral Tablet (DRUG), Ibudilast (DRUG).

Who is sponsoring clinical trial NCT03341078?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03341078's enrollment target sits among peer trials

176 394th of 2000 higher than 1,605 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03304821 · 176 participants · Phase 2

    Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

  • NCT03447938 · 176 participants · NA

    The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

  • NCT03824145 · 176 participants · NA

    Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

  • NCT04177914 · 176 participants · Phase 3

    HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03341078, the US trial registry maintained by the National Library of Medicine. NCT03341078 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.